Citation Tools
PDFRegular and young investigator award abstracts
Clinical trials in progress
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms